In this respect, although the MELK inhibitor MELK-8a is not approved for use in humans and future work is required to understand if this compound can effectively be used in patients, the ALK inhibitor AP is in clinical trials for patients with lung tumors43 and thus our discoveries not only uncover new druggable targets in BC but also suggest a re-purposing possibility for already available drugs to administer to specific BC patients carrying a specific tumor subtype. This evidence concerns the gene MELK and breast cancer.